Published in Semin Ophthalmol on May 21, 2003
Cataract surgery in patients with ocular surface disease: An update in clinical diagnosis and treatment. Saudi J Ophthalmol (2014) 0.88
Matrix metalloproteinases in recurrent corneal melting associated with primary Sjörgen's syndrome. Mol Vis (2009) 0.85
Laser in situ keratomileusis in patients with collagen vascular disease: a review of the literature. Clin Ophthalmol (2012) 0.76
Rheumatoid arthritis-associated corneal ulceration with superimposed infection by methicillin-resistant Staphylococcus aureus: a complicated type of corneal melt. Am J Case Rep (2014) 0.75
Peripheral Ulcerative Keratitis following Laser in situ Keratomileusis. Case Rep Ophthalmol (2016) 0.75
Spontaneous corneal perforation post cataract surgery. BMJ Case Rep (2011) 0.75
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea (2006) 3.18
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Plasmapheresis for lupus retinal vasculitis. Arch Ophthalmol (2006) 2.13
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Optimal size and location for corneal rotational autografts: a simplified mathematical model. Arch Ophthalmol (2006) 2.06
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85
Metaanalysis of cataract development after phakic intraocular lens surgery. J Cataract Refract Surg (2008) 1.79
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology (2005) 1.69
Relapsing polychondritis: a clinical review. Semin Arthritis Rheum (2002) 1.68
Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology (2007) 1.66
Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol (2004) 1.63
Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm (2010) 1.62
Ectatic disorders associated with a claw-shaped pattern on corneal topography. Am J Ophthalmol (2007) 1.61
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Ocular pemphigus. J Am Acad Dermatol (2005) 1.56
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
Combined ICRS insertion and LASIK to maximize postoperative residual bed thickness in high myopia. J Cataract Refract Surg (2004) 1.39
Laser eye surgery for refractive errors. Lancet (2006) 1.37
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Etiology and management of idiopathic orbital inflammation. Am J Ophthalmol (2004) 1.33
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology (2005) 1.33
Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin (2006) 1.25
Compositional differences between infant and adult human corneal basement membranes. Invest Ophthalmol Vis Sci (2007) 1.25
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol (2012) 1.21
Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res (2004) 1.20
Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology (2002) 1.20
Primary intraocular lymphoma: A review. Semin Ophthalmol (2006) 1.19
Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina (2009) 1.19
Management of traumatic cataracts. Int Ophthalmol Clin (2002) 1.18
360 degrees iris-ciliary body B-cell lymphoma masquerading as post-cataract uveitis. Semin Ophthalmol (2004) 1.18
Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol (2005) 1.17
Astigmatism outcomes of horizontal temporal versus nasal clear corneal incision cataract surgery. J Cataract Refract Surg (2004) 1.16
High-dose methotrexate for intraocular lymphoma. Clin Cancer Res (2003) 1.15
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Role of collagen-binding heat shock protein 47 and transforming growth factor-beta1 in conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2003) 1.14
Glaucoma and uveitis. Surv Ophthalmol (2012) 1.13
Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol (2007) 1.12
Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina (2007) 1.11
Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett (2005) 1.10
Anterior segment optical coherence tomography. Semin Ophthalmol (2010) 1.09
Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm (2008) 1.09
Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci (2003) 1.08
Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology (2005) 1.08
Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology (2003) 1.07
Scleritis therapy. Ophthalmology (2011) 1.07
Limbal stem cell transplantation in chronic inflammatory eye disease. Ophthalmology (2002) 1.07
Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey. J Cataract Refract Surg (2003) 1.07
Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology (2006) 1.07
Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm (2009) 1.06
Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol (2011) 1.05
Vogt-Koyanagi-Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy. Ophthalmic Surg Lasers Imaging (2009) 1.05
Evolution, techniques, clinical outcomes, and pathophysiology of LASEK: review of the literature. Surv Ophthalmol (2004) 1.05
The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol (2008) 1.04
Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am J Pathol (2009) 1.03
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
The spectrum of fundus autofluorescence findings in birdshot chorioretinopathy. J Ophthalmol (2010) 1.02
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm (2004) 1.02
Subconjunctival bevacizumab for corneal neovascularization. Cornea (2008) 1.02
Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol (2007) 1.01
Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology (2008) 1.01
Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol (2004) 1.01
The cell-layer- and cell-type-specific distribution of GalNAc-transferases in the ocular surface epithelia is altered during keratinization. Invest Ophthalmol Vis Sci (2003) 1.01
Infliximab for the treatment of refractory scleritis. Br J Ophthalmol (2009) 1.01
Visual outcome in herpes simplex virus and varicella zoster virus uveitis: a clinical evaluation and comparison. Ophthalmology (2002) 1.00
Cancer associated retinopathy (CAR): An autoimmune-mediated paraneoplastic syndrome. Semin Ophthalmol (2006) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm (2004) 0.99
Anti-angiogenic therapy: Prospects for treatment of ocular tumors. Semin Ophthalmol (2006) 0.98
Scleral necrosis in a patient with congenital erythropoietic porphyria. Cornea (2011) 0.98
Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett (2008) 0.98
Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol (2007) 0.97
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Safety, efficacy, and stability indices of LASEK correction in moderate myopia and astigmatism. J Cataract Refract Surg (2004) 0.97
Successful treatment of idiopathic orbital inflammation with mycophenolate mofetil. Am J Ophthalmol (2005) 0.97
Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Ophthalmology (2003) 0.96
Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm (2011) 0.96
Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol (2011) 0.96
Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol (2009) 0.96
Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol (2007) 0.96
Chronic postoperative endophthalmitis due to pseudomonas oryzihabitans. Am J Ophthalmol (2002) 0.96
Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology (2003) 0.96
A control-matched comparison of laser epithelial keratomileusis and laser in situ keratomileusis for low to moderate myopia. Am J Ophthalmol (2006) 0.95
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
Human corneal epithelial cell viability and morphology after dilute alcohol exposure. Invest Ophthalmol Vis Sci (2002) 0.95
Mitomycin-C assisted photorefractive keratectomy in the treatment of buttonholed laser in situ keratomileusis flaps associated with epithelial ingrowth. J Cataract Refract Surg (2005) 0.95
Surface ablation techniques. J Cataract Refract Surg (2011) 0.95
Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg (2005) 0.94
MT1-MMP-mediated cleavage of decorin in corneal angiogenesis. J Vasc Res (2009) 0.94
Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res (2004) 0.94